President, Inspirna Director since 2010 Age 69 Board Committees Compensation and Management Development Corporate Governance Key Skills Executive Leadership and Business Operations Drug Development Healthcare and Pharma Leadership Public Board Service Medicine and Scientific Research Relevant Expertise Dr. Rowinsky has extensive research and drug development and regulatory experience and broad scientific and medical knowledge. His experience leading teams that have registered more than twelve novel therapies for patients with advanced cancers enhances the Board s oversight of Biogen s R&D and quest to pioneer breakthrough innovations within the highly regulated life sciences industry. Career Highlights President, Inspirna, a privately held life science company (since 2015), and Executive Chairman (2016 2021) Chief Medical Officer, Hummingbird Biotherapeutics (2020 2023) Chief Scientific Officer, Clearpath Development, Inc. (2016 2021) Head of R&D, Chief Medical Officer, Stemline Therapeutics (2012 2015) CEO, Primrose Therapeutics, Inc., a biotech start-up (2010 2011) Chief Medical Officer, and Executive Vice President, ImClone Systems (2005 2010) Other Public Company Boards Current Purple Biotech Ltd. (since 2019) Verastem, Inc. (since 2017) Prior Fortress Biotech Inc. (2010 2024) Other Boards & Awards Director of the Institute, and Director of Clinical Research, Cancer Therapy & Research Center s Institute for Drug Development (1996 2004) Associate Professor of Oncology at the Johns Hopkins School of Medicine (1988 1996) Director, Scientific Counselors of the National Cancer Institute Level Panel on Access to Medicines Education B.A. in Liberal Arts, from New York University M.D. from Vanderbilt University School of Medicine